New and developing pharmacotherapies for hypertension

HÖCHT, CHRISTIAN; ALLO, MIGUEL A; POLIZIO, ARIEL HÉCTOR; MORETTÓN, MARCELA A; CARRANZA, ANDREA; CHIAPPETTA, DIEGO A; CHOI, MARCELO ROBERTO

Expert Review of Cardiovascular Therapy

Taylor and Francis Ltd.

Lugar: London; Año: 2022 vol. 20 p. 647 - 666

1477-9072

Introduction: Despite the significant contribution of hypertension to the global burden of disease, disease control remains poor worldwide. Considering this unmet clinical need, several new antihypertensive drugs with novel mechanisms of action are under development. Areas covered: The present review summarizes the recent advances in the development of emerging pharmacological agents for the management of hypertension. The latest technological innovations in the design of optimized formulations of available antihypertensive drugs and the potential role of the modification of intestinal microbiota to improve blood pressure (BP) control are also covered. Expert opinion: Significant efforts have been made to develop new antihypertensive agents with novel actions that target the main mechanisms involved in resistant hypertension. Sacubitril/valsartan may emerge as a potential first-line drug due to its superiority over renin angiotensin system inhibitors, and SGLT2 inhibitors can reduce BP in difficult-to-control hypertensive patients with type 2 diabetes. In addition, firibastat and aprocitentan may expand the therapeutic options for resistant hypertension by novel mechanism of actions. Since gut dysbiosis not only leads to hypertension but also causes direct target organ damage, prebiotics and probiotics could represent a potential strategy to prevent or reduce the development of hypertension and to contribute to BP control.